Franklin Street Advisors Inc. NC Grows Position in Merck & Co., Inc. $MRK

Franklin Street Advisors Inc. NC lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 462.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142,541 shares of the company’s stock after buying an additional 117,213 shares during the quarter. Franklin Street Advisors Inc. NC’s holdings in Merck & Co., Inc. were worth $15,004,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in MRK. DLD Asset Management LP raised its stake in shares of Merck & Co., Inc. by 30.1% during the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after buying an additional 11,000,000 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Merck & Co., Inc. by 192.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 5,496,664 shares of the company’s stock worth $461,335,000 after buying an additional 3,618,532 shares during the period. Invesco Ltd. raised its stake in shares of Merck & Co., Inc. by 16.6% during the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after buying an additional 2,821,766 shares during the period. Ameriprise Financial Inc. raised its stake in shares of Merck & Co., Inc. by 20.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock worth $1,336,877,000 after buying an additional 2,735,459 shares during the period. Finally, Corient Private Wealth LLC raised its stake in shares of Merck & Co., Inc. by 85.6% during the 2nd quarter. Corient Private Wealth LLC now owns 4,937,948 shares of the company’s stock worth $390,896,000 after buying an additional 2,277,088 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Merck & Co., Inc.

In related news, CMO Chirfi Guindo sold 20,000 shares of the stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total value of $2,437,600.00. Following the completion of the transaction, the chief marketing officer directly owned 80,615 shares of the company’s stock, valued at approximately $9,825,356.20. This represents a 19.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Caroline Litchfield sold 41,997 shares of the stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total value of $5,023,261.17. Following the completion of the transaction, the chief financial officer directly owned 90,192 shares of the company’s stock, valued at approximately $10,787,865.12. This represents a 31.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 320,176 shares of company stock worth $38,281,735 in the last quarter. 0.13% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MRK. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. JPMorgan Chase & Co. upped their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research note on Monday. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Wells Fargo & Company upped their target price on Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Finally, Guggenheim upped their target price on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $127.59.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck launched a cash tender offer to buy Terns Pharmaceuticals, accelerating an acquisition that expands its oncology and hematology pipeline ahead of patent expiries for key products — a strategic move that can support future revenue. Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
• Positive Sentiment: JPMorgan and other analysts have raised price targets / reiterated Overweight views on MRK, signaling institutional confidence that Merck shares still have upside — a catalyst for buying interest. JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock
• Positive Sentiment: Merck’s recent quarterly results beat estimates, revenue grew year-over-year and the company set FY2026 EPS guidance — underpinning valuation and investor confidence in near-term fundamentals. Strong Results Lifted Merck & Co (MRK) in Q4
• Positive Sentiment: Merck is highlighted among consistent dividend stocks, which can attract income-focused and defensive investors amid market uncertainty. Is Merck & Co. (MRK) One of the Best Consistent Dividend Stocks to Buy Right Now?
• Neutral Sentiment: Merck lowered its offer price for Terns after reviewing trial data, a detail that changes deal economics and signals the firm is calibrating cost vs. risk — ambiguous for MRK shareholders (lower cash outlay vs. potential pipeline concerns). Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
• Neutral Sentiment: Coverage pieces are reassessing Merck’s valuation after strong price momentum; momentum supports higher multiples, but some analysts flag S&P 500 reweighting and valuation headwinds. Assessing Merck (MRK) Valuation After Strong Recent Share Price Momentum
• Neutral Sentiment: Analysis explains the Terns deal’s role in Merck’s pipeline and how it could affect S&P 500 valuation exposure — useful context but not an immediate share-mover. Merck’s (NYSE:MRK) Terns Deal And S&P 500 Valuation Impact Explained
• Negative Sentiment: Some intraday weakness was reported recently as the broader market improved — a reminder that short-term pullbacks can occur even with positive headlines. Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
• Negative Sentiment: Commentary questioning whether Merck is overbought warns of near-term valuation risk after a big run — a potential headwind for momentum traders. Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought?

Merck & Co., Inc. Stock Up 3.3%

NYSE MRK opened at $123.25 on Thursday. The business has a fifty day moving average price of $118.54 and a 200 day moving average price of $104.06. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The company has a market cap of $304.73 billion, a P/E ratio of 16.93, a P/E/G ratio of 2.44 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. During the same period in the prior year, the company earned $1.72 EPS. The firm’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 16th were paid a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.